JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice
Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA
Excerpt from the Press Release:
BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monitoring protocol in clinical practice.
The publication1 reviews the clinical evidence for noninvasive surveillance, much of which evaluates the multicenter study data demonstrating the clinical utility of AlloMap® gene-expression profiling (GEP) and AlloSure® donor-derived cell-free DNA (dd-cfDNA). The authors also discuss the complementary role of GEP and dd-cfDNA and review the data suggesting that the tests can be used together for effective noninvasive rejection surveillance in heart transplant patients.
“CareDx is very proud to have helped clinicians shift their reliance on invasive EMBs to non-invasive solutions for routine heart transplant surveillance.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?